Sacubitril (24mg) and Valsartan (26mg): A Game-Changer in Heart Failure Treatment

Product Overview

SACUSMART 50 is a fixed-dose ARNI combination medication prescribed for the treatment of heart failure with reduced ejection fraction (HFrEF). The drug combines the benefits of Sacubitril, a neprilysin inhibitor, and Valsartan, an angiotensin II receptor blocker (ARB), to provide superior outcomes over traditional ACE inhibitors.

Sacubitril Valsartan Dose and Titration Guidelines

The sacubitril valsartan dose must be carefully adjusted based on the patient’s prior treatment history and tolerability:

Important: If switching from an ACE inhibitor, a 36-hour washout period is required before starting SACUSMART 50 to avoid the risk of angioedema.

Mechanism of Action

1. Sacubitril (24 mg):

Inhibits neprilysin, an enzyme responsible for breaking down natriuretic peptides, leading to:

• Vasodilation

• Sodium excretion (natriuresis)

• Reduced cardiac fibrosis

• Decreased blood pressure and volume overload

2. Valsartan (26 mg):

Blocks angiotensin II type-1 (AT1) receptors, thereby:

• Reducing vasoconstriction

• Lowering aldosterone levels

• Preventing myocardial remodeling

Together, these agents deliver synergistic cardiovascular protection, reducing strain on the heart and improving left ventricular function.

Indications

• Treatment of Chronic Heart Failure (HFrEF), especially in NYHA Class II-IV patients.

• Recommended for patients with reduced ejection fraction and/or a history of hospitalization for heart failure.

Clinical Benefits of SACUSMART 50

✔ Reduced cardiovascular mortality
✔ Lower risk of hospitalization due to heart failure
✔ Enhanced cardiac function and ejection fraction
✔ Improved patient quality of life
✔ Safe, effective, and well-tolerated

Backed by the landmark PARADIGM-HF trial, ARNI therapy with sacubitril valsartan has demonstrated superiority over enalapril in reducing the composite endpoint of cardiovascular death and heart failure hospitalization.

Sacubitril Valsartan Dose Adjustment in Special Populations

Common Side Effects

While SACUSMART 50 is generally well-tolerated, some patients may experience:

• Low blood pressure (hypotension)

• Elevated potassium levels (hyperkalemia)

• Dizziness or lightheadedness

• Kidney function impairment

• Fatigue

• Rare risk of angioedema

Routine monitoring of blood pressure, serum potassium, and renal parameters is advised during treatment.

Contraindications

Avoid SACUSMART 50 in patients with:

• History of angioedema related to previous RAAS inhibitor therapy

• Pregnancy or lactation

• Concomitant ACE inhibitor use

• Severe hepatic impairment

Drug Interactions

• ACE inhibitors (requires a 36-hour washout)

• Potassium-sparing diuretics (increased risk of hyperkalemia)

• NSAIDs (may reduce renal function)

• Lithium (risk of lithium toxicity)

Storage & Handling

• Store in a cool, dry place, below 30°C

• Protect from light and moisture

• Keep out of reach of children

Product Summary Table

Frequently Asked Questions

Q1. What is the initial sacubitril valsartan dose for heart failure patients?

Answer: The recommended starting dose is SACUSMART 50 (24 mg/26 mg) twice daily, especially in patients not previously on a RAAS inhibitor or who have low blood pressure.

Q2. How long should SACUSMART 50 be taken?

Answer: It is intended for long-term, lifelong management of chronic heart failure under medical supervision.

Q3. Can SACUSMART 50 replace ACE inhibitors?

Answer: Yes, but only after a 36-hour washout period. SACUSMART has proven to be superior to enalapril in reducing heart failure mortality and hospitalizations.

Conclusion

SACUSMART 50, containing Sacubitril (24 mg) and Valsartan (26 mg), is a clinically validated, guideline-recommended treatment for heart failure patients with reduced ejection fraction. It offers a robust mechanism of action, excellent tolerability, and a well-defined sacubitril valsartan dose strategy for optimal results. SACUSMART 50 is an essential first step in transforming heart failure management, improving patient outcomes, and enhancing quality of life.

About The Author

STERIS HEALTHCARE PVT LTD

Steris Healthcare Pvt Ltd, known as Sterispharma, was founded in February 2018 by a team of experienced professionals in the pharmaceutical industry. Headquartered in Navi Mumbai, the company holds certifications from WHO, GMP, and ISO, reflecting its dedication to maintaining high standards of quality and safety. Sterispharma’s mission is to provide affordable, high-quality medications across India, strictly adhering to WHO guidelines. With the convenience of an online pharmacy, customers can easily order medicines with home delivery options.

For further information 

Email: info@sterispharma.com / contact@sterispharma.com

Call/WhatsApp: 8209542042 , 8824175417

BUY NOW